Clinical Trial · NCT01308905

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

Overview

The purpose of this study is to gain knowledge about how to best diagnose and treat tumors, how tumors affect normal tissue and how treatment of tumors with radiation therapy and chemotherapy affect tumors.

Sponsor

Barbara Ann Karmanos Cancer Institute

Phase

N/A

Contacts

Zhihong J Wang, M.D., Ph.D. (CONTACT)

jwang2@wayne.edu

(313) 966-7772

Anthony F. Shields, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Anthony F Shields, M.D., Ph.D (CONTACT)

shieldsa@karmanos.org

(313) 576-8735

ClinicalTrials.gov

NCT01308905

Drug / Compound

FLT

Isotope(s):

Target(s):

cytosolic thymidine kinase 1

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients must be able to lie still for the tests, or have no contraindication for sedation
Diagnosis: All patients with neuroblastoma or suspected neuroblastoma, including newly diagnosed and relapsed patients, are eligible for Objective 1. To be eligible for Objective 2, patients must have a diagnosis of neuroblastoma verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites, and have measurable disease after the initial surgery
A total number of 40-50 patients will be included in the study
Female adolescent patients must have a negative pregnancy test within 14 days of first imaging and should not be pregnant

Exclusion

Patients who do not have a histology diagnosis of neuroblastoma are not eligible for the study
Patients whose definite diagnosis after surgery is not consistent with the diagnosis of neuroblastoma will be included in the Objective 1 but excluded for Objective 2.